文献速递免疫规划妇幼与学校卫生

坦桑尼亚9-14岁女孩单剂与两剂人乳头瘤病毒疫苗接种后5年免疫原性持久性比较:DoRIS随机试验长期扩展结果

Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.
PubMed 文献 · Lancet Glob Health · 2025-01-01

DoRIS随机试验长期扩展在坦桑尼亚9-14岁女孩中比较单剂与两剂HPV疫苗5年免疫原性。单剂组HPV16血清阳性率>99%且非劣于两剂;HPV18单剂组二价疫苗98%、九价疫苗93%血清阳性,但未达非劣效标准。单剂组抗体GMC低于两剂组,但12至60月保持稳定。

要点

  • 单剂HPV16血清阳性率>99%,非劣于两剂
  • HPV18单剂组二价98%、九价93%阳性,未达非劣效
  • 单剂组GMC低于两剂但12-60月稳定

核心结论

  • 9-14岁女孩单剂HPV疫苗接种后5年仍提供稳定免疫应答,但需持续监测单剂后免疫可能减弱。
  • 参与者正随访至接种后9年。

研究设计与样本

  • 开放标签随机对照试验DoRIS长期扩展,930名坦桑尼亚9-14岁女学生随机分配至一剂、两剂或三剂二价疫苗(Cervarix)或九价疫苗(Gardasil-9)组。
  • 一剂和两剂组随访至第60月,主要结局为HPV16或HPV18血清阳性率比较。

主要发现

  • 第60月单剂组任一疫苗HPV16 IgG血清阳性率>99%,非劣于两剂组。
  • 第60月HPV18血清阳性率:单剂二价组98%,单剂九价组93%,单剂与两剂比较未达非劣效标准。
  • 单剂组HPV16和HPV18抗体GMC低于两剂组,但单剂组GMC从第12月至第60月保持稳定。
  • 第36月单剂与两剂组间HPV16或HPV18抗体亲和力无差异证据。

临床怎么用

  • 作者指出单剂HPV疫苗在9-14岁女孩中5年仍提供稳定免疫应答,但需持续监测单剂后免疫可能减弱。

局限性

  • 需持续监测单剂后免疫可能减弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: WHO has recommended that one dose of human papillomavirus (HPV) vaccine can be given to individuals aged 9-20 years to prevent HPV infection. Estimating durability of immune responses after a single dose in the target age for vaccination is important. We report immunogenicity results in Tanzanian girls up to 5 years after receiving a dose. METHODS: In this open-label, randomised controlled trial (the Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls [DoRIS] trial), 930 Tanzanian schoolgirls aged 9-14 years were enrolled and randomly allocated to receive one, two, or three doses of either the two-valent vaccine (Cervarix; GSK, Wavre, Belgium) or nine-valent vaccine (Gardasil-9; Merck Sharp & Dohme, Haarlem, Netherlands). Seropositivity specific to HPV16 or HPV18, antibody geometric mean concentrations (GMCs), and antibody avidity were measured annually up to month 36. Participants in the one-dose and two-dose groups were followed annually in a long-term extension of the DoRIS trial to month 60; the primary outcome was seropositivity specific to HPV16 or HPV18 comparing one dose with two doses. FINDINGS: Single-dose seropositivity for HPV16 IgG antibodies at month 60 with either vaccine was more than 99% and non-inferior to two doses. 98% of girls in the one-dose two-valent vaccine group and 93% in the one-dose nine-valent group were seropositive for HPV18 at month 60; however, the non-inferiority criteria for HPV18 seropositivity comparing one dose with two doses were not met. Although HPV16 and HPV18 antibody GMCs after one dose were lower than those observed after two doses, antibody GMCs in the one-dose groups remained stable from month 12 to month 60. There was no evidence of a difference between the one-dose and two-dose groups in HPV16 or HPV18 antibody avidity at month 36 for either vaccine. INTERPRETATION: A single dose of HPV vaccine in girls aged 9-14 years continues to provide stable immune responses 5 years after vaccination, although ongoing surveillance for potential waning immunity after a single dose is needed. Participants are being followed up to 9 years after vaccination. FUNDING: UK Department of Health and Social Care, UK Foreign, Commonwealth & Development Office, Global Challenges Research Fund, UK Medical Research Council, and the Wellcome Trust through the Joint Global Health Trials Scheme; Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Watson-Jones D, Changalucha J, Maxwell C, et al. Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial. Lancet Glob Health. 2025. PMID: 39890232. doi:10.1016/S2214-109X(24)00477-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。